Zymeworks garners $8.1M in venture cash; Cardio3 opens U.S. office; CMC completes $10M manufacturing expansion;

 

@FierceBiotech: Good read. MT @ScottKirsner: Things entrepreneurs say that prevent investors from taking them seriously. Article | Follow @FierceBiotech

@JohnCFierce: Good to see Ambrx, Fierce 15 class of 2005, doing well. String of deals helped finance co. And BMS is a good partner. Report | Follow @JohnCFierce

@RyanMFierce: See who's betting big on a new cardiac device (via @FierceMedDev). Story | Follow @RyanMFierce

@MaureenFierce: Study: Removing cholesterol from HIV boosts second immune response. Report | Follow @MaureenFierce

@FierceMedDev: Former Wright exec takes reins at Intrinsic. Piece | Follow @FierceMedDev

> Canada's Zymeworks has hauled in $8.1 million in new venture cash to support its development of antibodies and next-gen protein-based therapeutics. The follow-on round came from CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund and several private shareholders. Release

> Belgium's Cardio3 has established a U.S. office as it prepares to collaborate with the Mayo Clinic on a late-stage trial for heart failure. the biotech reported positive mid-stage data from its stem cell study last year. Story

> Seattle's CMC Biologics has completed a $10 million expansion of its manufacturing facilities, doubling its capacity to deliver biologics for clinical studies and adding commercial supplies to the mix. Story

> Spain's Digna Biotech won the FDA's orphan status for cardiotrophin-1 in the treatment of acute liver failure. Release

Pharma News

@FiercePharma: Chinese drugmakers turn up heat on India. Story | Follow @FiercePharma

> VA puts cork in Avastin use for eye disease. News

> French pharma boss singled out in Mediator probe. More

> Court grants favorable decision to Warner Chilcott in Doryx dispute. Piece

Vaccines News

> RXi licenses ovarian cancer vax. Item

> Researchers: Whooping cough vaccine fades after 3 years. Story

> Study: Vaccinating children against flu cuts ER visits. Article

> Sanofi aims for acne vaccine in new pact. News

Manufacturing News

> Pfizer's Grange Castle to be QC mecca. Story

> Rx-360 launch reinforces benefits of shared audits. News

> Chinese drugmakers turn up heat on India. Article

> With help from state, GSK adds jobs in Montana. Report

> DHL jockeys for pharma logistics biz in China. Item

> West-Ward sees shortages as 'major opportunity.' Report

And Finally... Investigators say that deep brain stimulation can spur the development of memory cells. "DBS has been quite effective for the treatment of movement disorders, such as Parkinson's disease, and has recently been explored for treatment of a range of neurologic and psychiatric conditions," said Paul Frankland, PhD, of The Hospital for Sick Children. Release

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.